Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAPK8_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAPK8_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAPK8_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAPK8_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAPK8_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAPK8_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAPK8_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAPK8_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAPK8_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAPK8_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:003315722 | Oral cavity | EOLP | regulation of intracellular protein transport | 63/2218 | 229/18723 | 7.28e-11 | 9.09e-09 | 63 |
GO:003164726 | Oral cavity | EOLP | regulation of protein stability | 75/2218 | 298/18723 | 1.22e-10 | 1.35e-08 | 75 |
GO:005122225 | Oral cavity | EOLP | positive regulation of protein transport | 72/2218 | 303/18723 | 4.20e-09 | 2.41e-07 | 72 |
GO:000756825 | Oral cavity | EOLP | aging | 78/2218 | 339/18723 | 4.55e-09 | 2.55e-07 | 78 |
GO:003238822 | Oral cavity | EOLP | positive regulation of intracellular transport | 54/2218 | 202/18723 | 4.95e-09 | 2.74e-07 | 54 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:001050622 | Oral cavity | EOLP | regulation of autophagy | 74/2218 | 317/18723 | 5.84e-09 | 3.07e-07 | 74 |
GO:005082126 | Oral cavity | EOLP | protein stabilization | 51/2218 | 191/18723 | 1.37e-08 | 6.40e-07 | 51 |
GO:190495125 | Oral cavity | EOLP | positive regulation of establishment of protein localization | 73/2218 | 319/18723 | 1.80e-08 | 7.94e-07 | 73 |
GO:004851117 | Oral cavity | EOLP | rhythmic process | 69/2218 | 298/18723 | 2.68e-08 | 1.11e-06 | 69 |
GO:005109824 | Oral cavity | EOLP | regulation of binding | 79/2218 | 363/18723 | 4.86e-08 | 1.81e-06 | 79 |
GO:000030225 | Oral cavity | EOLP | response to reactive oxygen species | 55/2218 | 222/18723 | 6.27e-08 | 2.29e-06 | 55 |
GO:003109923 | Oral cavity | EOLP | regeneration | 50/2218 | 198/18723 | 1.30e-07 | 4.25e-06 | 50 |
GO:190382925 | Oral cavity | EOLP | positive regulation of cellular protein localization | 63/2218 | 276/18723 | 1.84e-07 | 5.87e-06 | 63 |
GO:001623622 | Oral cavity | EOLP | macroautophagy | 65/2218 | 291/18723 | 2.74e-07 | 8.26e-06 | 65 |
GO:009031622 | Oral cavity | EOLP | positive regulation of intracellular protein transport | 42/2218 | 160/18723 | 4.18e-07 | 1.19e-05 | 42 |
GO:001624121 | Oral cavity | EOLP | regulation of macroautophagy | 38/2218 | 141/18723 | 7.18e-07 | 1.83e-05 | 38 |
GO:001821015 | Oral cavity | EOLP | peptidyl-threonine modification | 35/2218 | 125/18723 | 7.33e-07 | 1.85e-05 | 35 |
GO:001810715 | Oral cavity | EOLP | peptidyl-threonine phosphorylation | 33/2218 | 116/18723 | 1.02e-06 | 2.51e-05 | 33 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | JNJ-7706621 | JNJ-7706621 | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | OXYTOCIN | OXYTOCIN | 11566737 |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | CYC-116 | CYC-116 | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | CI-1040 | CI-1040 | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | CHEMBL1950289 | TANZISERTIB | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | CENISERTIB | CENISERTIB | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | sorafenib | SORAFENIB | 20124951 |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565738 | | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 374883876 | | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | KEYHOLE LIMPET HEMOCYANIN | | 15857404 |